Literature DB >> 30203415

A meta-analysis identified genes responsible for distinct immune responses to trivalent inactivated and live attenuated influenza vaccines.

Feng Wen1,2, Jinyue Guo1, Shujian Huang1.   

Abstract

Vaccinations are the cornerstone of influenza prevention strategies. We carried out a meta-analysis of the messenger RNA expression profiles from recipients of trivalent inactivated vaccines (TIV) or live attenuated vaccines (LAIV) to determine the different recipients' responses to these two types of vaccines, which may provide information to improve the design of future improved vaccines. We executed meta-analysis on these datasets using a random-effects model and identified 191 and 195 differentially expressed genes in TIV and LAIV, respectively, with an false discovery rate <0.05. The genes significantly upregulated by TIV were associated with both the innate immune response and the humoral immune response, whereas LAIV mainly activated the innate immune system. The identified genes that responsible for the immune difference between LAIV and TIV might provide new information to improve current vaccines to have better efficacy in children, adults, and the elderly.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  live attenuated vaccines; meta-analysis; seasonal influenza; trivalent inactivated vaccines

Mesh:

Substances:

Year:  2018        PMID: 30203415     DOI: 10.1002/jcp.27327

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  2 in total

Review 1.  How to assess the effectiveness of nasal influenza vaccines? Role and measurement of sIgA in mucosal secretions.

Authors:  Elena Gianchecchi; Alessandro Manenti; Otfried Kistner; Claudia Trombetta; Ilaria Manini; Emanuele Montomoli
Journal:  Influenza Other Respir Viruses       Date:  2019-06-21       Impact factor: 4.380

2.  A panel of 8 miRNAs as a novel diagnostic biomarker in pancreatic cancer.

Authors:  Benyuan Deng; Ming Wang; Zhongwu Liu
Journal:  Medicine (Baltimore)       Date:  2020-09-18       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.